Ymmunobio Achieves Major Preclinical Milestone with YB-800 ADCs

RIEHEN, Switzerland, April 18, 2025 /PRNewswire/ -- Ymmunobio AG (YB), a Swiss-based global biotech company dedicated to the development of new cancer therapeutics, is proud to announce that its two-antibody drug conjugate (ADC) assets, YB-800ADC1 and YB-800ADC2, have completed the preclinical proof of concept studies. Both in vivo and in vitro studies have reached this important milestone by demonstrating the anti-tumor efficacy of both ADCs.

Read the full report here.